The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic dermatitis. One of the most highly-anticipated approvals of 2017, Dupixent is the latest output of the collaboration between Sanofi and Regeneron. While Dupixent is exciting for several reasons, its pricing strategy is...
Why drug pricing is in the news now and what can be done about it? From Turing Pharmaceuticals to Mylan, there has been no shortage of news coverage on the high cost of prescription drugs. While politicians and drug companies have fought the issue in the...
ACA repeal and replacement complicated by two key challenges With President-elect Donald Trump officially taking office, Republicans are working to finally fulfill their promise to repeal the Affordable Card Act (ACA), commonly referred to as ObamaCare. However, despite the Republicans eagerness to put the ACA behind...
Extending market exclusivity and responding properly to the volume of recent patent expiries are critical to the sustainability of pharmaceutical corporations. In the midst of the 2012-2019 patent cliff, the period during which market exclusivity for top-selling biologics is jeopardized, pharmaceutical corporations have been...
2016 proved to be less than stellar for pharmaceutical companies for a number of reasons, not least being a low point for marketing approval of new products (22 in 2016). While the industry continues to shift the focus of R&D efforts towards compounds that carve...
Vermont recently became the first state to pass a law requiring pharmaceutical manufacturers to either disclose and explain company rationale for product price increases or face legal consequences. People within the industry naturally started to panic, as evidenced by numerous news articles. However, those who...
Every year, our bike-enthusiast team members eagerly await the national American Diabetes Association (ADA) Tour de Cure event. It’s a chance for the team to get some fresh air and exercise while helping raise money to find a cure for diabetes. Nearly 30 million people battle...